These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10602778)

  • 21. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.
    Clark RE
    Leuk Lymphoma; 1995 Oct; 19(3-4):189-95. PubMed ID: 8535209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
    Szczylik C; Skorski T; Nicolaides NC; Manzella L; Malaguarnera L; Venturelli D; Gewirtz AM; Calabretta B
    Science; 1991 Aug; 253(5019):562-5. PubMed ID: 1857987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination with an antisense oligonucleotide synergistically improves the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium in chronic myeloid leukemia cell lines.
    Konstantinov SM; Georgieva MC; Topashka-Ancheva M; Eibl H; Berger MR
    Mol Cancer Ther; 2002 Aug; 1(10):877-84. PubMed ID: 12492121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced growth suppression of Philadephia1 leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy.
    Cong XL; Li B; Yang RC; Feng SZ; Chen SJ; Han ZC
    Leukemia; 2005 Sep; 19(9):1517-24. PubMed ID: 16034468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.
    Giles RV; Spiller DG; Green JA; Clark RE; Tidd DM
    Blood; 1995 Jul; 86(2):744-54. PubMed ID: 7606003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
    Zhang JH; He YL; Zhu R; Du W; Xiao JH
    Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
    de Fabritiis P; Amadori S; Calabretta B; Mandelli F
    Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids.
    Rapozzi V; Burm BE; Cogoi S; van der Marel GA; van Boom JH; Quadrifoglio F; Xodo LE
    Nucleic Acids Res; 2002 Sep; 30(17):3712-21. PubMed ID: 12202756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
    Lin H; Monaco G; Sun T; Ling X; Stephens C; Xie S; Belmont J; Arlinghaus R
    Oncogene; 2005 May; 24(20):3246-56. PubMed ID: 15735695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines.
    Algar EM; Khromykh T; Smith SI; Blackburn DM; Bryson GJ; Smith PJ
    Oncogene; 1996 Mar; 12(5):1005-14. PubMed ID: 8649791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
    Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection and direct sequence identification of BCR-ABL mRNA in Ph+ chronic myeloid leukemia.
    Sooknanan R; Malek L; Wang XH; Siebert T; Keating A
    Exp Hematol; 1993 Dec; 21(13):1719-24. PubMed ID: 8243571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D; Hanenberg H; Lion T; Burdach S
    Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes).
    Wu Y; Yu L; McMahon R; Rossi JJ; Forman SJ; Snyder DS
    Hum Gene Ther; 1999 Nov; 10(17):2847-57. PubMed ID: 10584930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specificity of BCR-ABL antisense oligonucleotides.
    Smetsers TF; Mensink EJ
    Blood; 1995 Jan; 85(2):597-8. PubMed ID: 7812014
    [No Abstract]   [Full Text] [Related]  

  • 37. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
    Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.
    Gryaznov S; Skorski T; Cucco C; Nieborowska-Skorska M; Chiu CY; Lloyd D; Chen JK; Koziolkiewicz M; Calabretta B
    Nucleic Acids Res; 1996 Apr; 24(8):1508-14. PubMed ID: 8628685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia.
    Tari AM; Tucker SD; Deisseroth A; Lopez-Berestein G
    Blood; 1994 Jul; 84(2):601-7. PubMed ID: 8025286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.